Mouse IL-2/CD25 Fusion Protein Induces Regulatory T Cell Expansion and Immune Suppression in Preclinical Models of Systemic Lupus Erythematosus

Regulatory T cells are less sensitive to glucocorticoid hormone induced apoptosis than CD4+ T cells

(2020) Lilla Prenek et al.   APOPTOSIS

Persistent IL-2 Receptor Signaling by IL-2/CD25 Fusion Protein Controls Diabetes in NOD Mice by Multiple Mechanisms

(2020) Natasha C. Ward et al.   DIABETES

Autoimmune pathways in mice and humans are blocked by pharmacological stabilization of the TYK2 pseudokinase domain

(2019) James R. Burke et al.   Science Translational Medicine

Pharmacodynamics of regulatory T cells in mice and humans treated with low-dose IL-2

(2018) Guillaume Churlaud et al.   JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY

Regulatory T cells in autoimmune disease

(2018) Margarita Dominguez-Villar et al.   NATURE IMMUNOLOGY

Regulatory T-Cells: Potential Regulator of Tissue Repair and Regeneration

(2018) Jiatao Li et al.   Frontiers in Immunology

Immunological and clinical effects of low-dose interleukin-2 across 11 autoimmune diseases in a single, open clinical trial

(2018) Michelle Rosenzwajg et al.   ANNALS OF THE RHEUMATIC DISEASES

IL-2/CD25: A Long-Acting Fusion Protein That Promotes Immune Tolerance by Selectively Targeting the IL-2 Receptor on Regulatory T Cells

(2018) Natasha C. Ward et al.   JOURNAL OF IMMUNOLOGY

Restoring regulation – IL-2 therapy in systemic lupus erythematosus

(2016) Jens Y. Humrich et al.   Expert Review of Clinical Immunology

Long-term organ damage accrual and safety in patients with SLE treated with belimumab plus standard of care

(2016) I N Bruce et al.   LUPUS

Low-dose interleukin-2 treatment selectively modulates CD4+ T cell subsets in patients with systemic lupus erythematosus

(2016) Jing He et al.   NATURE MEDICINE

Low-dose interleukin-2 selectively corrects regulatory T cell defects in patients with systemic lupus erythematosus

(2015) Caroline von Spee-Mayer et al.   ANNALS OF THE RHEUMATIC DISEASES

Low-dose interleukin-2 fosters a dose-dependent regulatory T cell tuned milieu in T1D patients

(2015) Michelle Rosenzwajg et al.   JOURNAL OF AUTOIMMUNITY

T cells in the control of organ-specific autoimmunity

(2015) Jeffrey A. Bluestone et al.   JOURNAL OF CLINICAL INVESTIGATION

Engineering of a Novel Anti-CD40L Domain Antibody for Treatment of Autoimmune Diseases

(2014) J. H. Xie et al.   JOURNAL OF IMMUNOLOGY

The need to define treatment goals for systemic lupus erythematosus

(2014) Kate Franklyn et al.   Nature Reviews Rheumatology

Effects of Low-Dose Recombinant Interleukin 2 to Promote T-Regulatory Cells in Alopecia Areata

(2014) Emeline Castela et al.   JAMA Dermatology

High dose interleukin-2 (Aldesleukin) - expert consensus on best management practices-2014

(2014) Janice P Dutcher et al.   Journal for ImmunoTherapy of Cancer

IL-2R Signaling Is Essential for Functional Maturation of Regulatory T Cells during Thymic Development

(2013) G. Cheng et al.   JOURNAL OF IMMUNOLOGY

Systemic Lupus Erythematosus

(2011) George C. Tsokos   NEW ENGLAND JOURNAL OF MEDICINE

Regulatory T-Cell Responses to Low-Dose Interleukin-2 in HCV-Induced Vasculitis

(2011) David Saadoun et al.   NEW ENGLAND JOURNAL OF MEDICINE

Interleukin-2 and Regulatory T Cells in Graft-versus-Host Disease

(2011) John Koreth et al.   NEW ENGLAND JOURNAL OF MEDICINE

IL-2 reverses established type 1 diabetes in NOD mice by a local effect on pancreatic regulatory T cells

(2010) Yenkel Grinberg-Bleyer et al.   JOURNAL OF EXPERIMENTAL MEDICINE

A Low Interleukin-2 Receptor Signaling Threshold Supports the Development and Homeostasis of T Regulatory Cells

(2009) Aixin Yu et al.   IMMUNITY

Serious infections in British patients with systemic lupus erythematosus: hospitalisations and mortality

(2009) F Goldblatt et al.   LUPUS

Central Role of Defective Interleukin-2 Production in the Triggering of Islet Autoimmune Destruction

(2008) Qizhi Tang et al.   IMMUNITY